Moolec Science SAMLEC
Price$4.81

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $5.6M+521.5% YoYTTM through 31 Dec 2024
Net Income -$7.3MTTM through 31 Dec 2024
Free Cash Flow -$9.5MTTM through 31 Dec 2024

Margins

Current
Gross Margin8.4%
EBITDA Margin-160.3%
Operating Margin-160.8%
Net Margin-130.0%

Returns

-261.5%ROE
-23.3%ROA

Balance Sheet Health

Debt / Equity5.26x
Current Ratio1.48x
Net Debt$12.8M
Cash & Equivalents$1.9M

Quality Metrics

Piotroski F-Score3 / 9
FCF Margin-168.6%

Multi-Year Trend

Revenue
'23'24
FY2024: $5.6M
Diluted EPS
'22'23'24
FY2024: $-0.19

Dividend

No dividend

Capital Allocation

Capex Intensity2.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.